Propol2 EMF, Ruscoven, Serenil, Fisiodepur and Finocarbo will become part of Zentiva’s portfolio
Zentiva announced the acquisition of five heritage brands from Aboca that will widen access to well-known natural treatments across Europe; due to take effect on 30 June 2025.
Health Technology Insights: Sky Labs at Forefront of Cuffless Blood Pressure Monitoring
The acquisition reinforces Zentiva’s ambition to become a leading Consumer Healthcare player. While the deal has a particular emphasis on the markets in Italy, Spain and France, its scope also covers other countries including Portugal, Poland, Romania, and Greece.
By integrating the newly acquired brands from the Aboca herbal portfolio, Zentiva will immediately strengthen its position in three key and fast-growing self-care categories: Respiratory, Circulatory, and Calm & Sleep, aligning with market trends and fast-growing consumer demand for natural, sustainably sourced products. The combined expertise will accelerate Zentiva’s growth in Western Europe and complement its established CHC leadership in Central-Eastern Europe.
Health Technology Insights: Datavant to Acquire Ontellus, Boosting Medical Record Retrieval and Claims Intelligence
Steffen Saltofte, Chief Executive Officer, Zentiva, said: “Natural self-care is no longer a niche; it is what consumers, pharmacists and healthcare systems increasingly expect. Combining Zentiva’s consumer healthcare reach with Aboca expertise in plant-based science is the perfect fit for our CHC growth strategy and for our purpose of providing health and wellbeing for all generations.”
The agreement adds value to Zentiva’s portfolio ensuring greater category leadership, with Aboca brands such as Propol2 EMF (Respiratory), Ruscoven (Circulatory) and Serenil (Calm & Sleep), complementing Zentiva’s existing CHC range. It also lays the foundation for long-term growth through future portfolio and geographic extensions.
Health Technology Insights: athenahealth, Humana and Your Health Close Care Gaps, Cut Clinician Admin Burden
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source – PR Newswire
